These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 23604754)

  • 21. Dysfunctional HDL: a novel important diagnostic and therapeutic target in cardiovascular disease?
    Otocka-Kmiecik A; Mikhailidis DP; Nicholls SJ; Davidson M; Rysz J; Banach M
    Prog Lipid Res; 2012 Oct; 51(4):314-24. PubMed ID: 22609245
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Perspective. The failure of cholesteryl ester transfer protein inhibitors: is it due to increased blood viscosity?
    Sloop GD; Weidman JJ; St Cyr JA
    Ther Adv Cardiovasc Dis; 2015 Apr; 9(2):32-5. PubMed ID: 25573766
    [No Abstract]   [Full Text] [Related]  

  • 23. HDL-Targeting Therapeutics: Past, Present and Future.
    Zakiev E; Feng M; Sukhorukov V; Kontush A
    Curr Pharm Des; 2017; 23(8):1207-1215. PubMed ID: 27799042
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Journey through cholesteryl ester transfer protein inhibition: from bench to bedside.
    Karalis I; Rensen PC; Jukema JW
    Circ Cardiovasc Qual Outcomes; 2013 May; 6(3):360-6. PubMed ID: 23674310
    [No Abstract]   [Full Text] [Related]  

  • 25. Cholesteryl ester transfer protein (CETP) inhibitors: is there life after torcetrapib?
    Neeli H; Rader DJ
    Cardiol Clin; 2008 Nov; 26(4):537-46. PubMed ID: 18929230
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Therapy and clinical trials.
    Elmallah W; Krasuski RA
    Curr Opin Lipidol; 2011 Dec; 22(6):512-3. PubMed ID: 22101564
    [No Abstract]   [Full Text] [Related]  

  • 27. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP as a Target to Lower CVD Risk: Suspension of Disbelief?
    Hovingh GK; Ray KK; Boekholdt SM
    Circulation; 2015 Aug; 132(5):433-40. PubMed ID: 26240264
    [No Abstract]   [Full Text] [Related]  

  • 28. Cholesteryl ester transfer protein inhibition to reduce cardiovascular risk: Where are we now?
    Barter P; Rye KA
    Trends Pharmacol Sci; 2011 Dec; 32(12):694-9. PubMed ID: 22088767
    [TBL] [Abstract][Full Text] [Related]  

  • 29. 2nd International Symposium on Triglycerides and HDL: lipid abnormalities and their treatment.
    Bloomgarden ZT
    Diabetes Care; 2005 Nov; 28(11):2795-802. PubMed ID: 16249560
    [No Abstract]   [Full Text] [Related]  

  • 30. High-density lipoprotein particles, coronary heart disease, and niacin.
    Asztalos BF
    J Clin Lipidol; 2010; 4(5):405-10. PubMed ID: 21122684
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Torcetrapib as potential treatment of low high-density lipoprotein cholesterol: no longer a pipe dream?
    Ahmed MH
    Diabetes Technol Ther; 2008 Aug; 10(4):328-9. PubMed ID: 18715207
    [No Abstract]   [Full Text] [Related]  

  • 32. New focus on raising HDL "good" cholesterol. But the value of this is not entirely clear.
    Duke Med Health News; 2012 Feb; 18(2):3. PubMed ID: 22397008
    [No Abstract]   [Full Text] [Related]  

  • 33. Dalcetrapib in patients with an acute coronary syndrome.
    Tomoda H
    N Engl J Med; 2013 Feb; 368(9):869. PubMed ID: 23445099
    [No Abstract]   [Full Text] [Related]  

  • 34. Dalcetrapib in patients with an acute coronary syndrome.
    Schwartz GG; Olsson AG; Barter PJ
    N Engl J Med; 2013 Feb; 368(9):869-70. PubMed ID: 23445098
    [No Abstract]   [Full Text] [Related]  

  • 35. Different effects of compounds decreasing cholesteryl ester transfer protein activity on lipoprotein metabolism.
    Niesor EJ
    Curr Opin Lipidol; 2011 Aug; 22(4):288-95. PubMed ID: 21587074
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The failure of torcetrapib: was it the molecule or the mechanism?
    Tall AR; Yvan-Charvet L; Wang N
    Arterioscler Thromb Vasc Biol; 2007 Feb; 27(2):257-60. PubMed ID: 17229967
    [No Abstract]   [Full Text] [Related]  

  • 37. Is Cholesteryl Ester Transfer Protein Inhibition an Effective Strategy to Reduce Cardiovascular Risk? CETP Inhibition as a Strategy to Reduce Cardiovascular Risk: The Pro Case.
    Barter PJ; Nicholls SJ; Kastelein JJ; Rye KA
    Circulation; 2015 Aug; 132(5):423-32. PubMed ID: 26240263
    [No Abstract]   [Full Text] [Related]  

  • 38. CETP inhibition in perspective.
    Stock J
    Atherosclerosis; 2012 Feb; 220(2):325-8. PubMed ID: 22079329
    [No Abstract]   [Full Text] [Related]  

  • 39. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 40. The potential for CETP inhibition to reduce cardiovascular disease risk.
    Ansell B; Hobbs FD
    Curr Med Res Opin; 2006 Dec; 22(12):2467-78. PubMed ID: 17257461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.